Veracyte Inc VCYT.OQ VCYT.O is expected to show a rise in quarterly revenue when it reports results on November 4 for the period ending September 30 2025
The South San Francisco California-based company is expected to report a 7.8% increase in revenue to $124.917 million from $115.86 million a year ago, according to the mean estimate from 10 analysts, based on LSEG data.
LSEG's mean analyst estimate for Veracyte Inc is for earnings of 13 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Veracyte Inc is $43.50, about 18.8% above its last closing price of $35.33
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | 0.11 | 0.10 | -0.01 | Missed | -110.5 |
Mar. 31 2025 | 0.03 | 0.05 | 0.09 | Beat | 75.6 |
Dec. 31 2024 | 0.11 | 0.11 | 0.06 | Missed | -47.5 |
Sep. 30 2024 | 0.03 | 0.03 | 0.19 | Beat | 592.7 |
Jun. 30 2024 | -0.01 | -0.02 | 0.07 | Beat | 530.8 |
Mar. 31 2024 | -0.18 | -0.16 | -0.02 | Beat | 87.4 |
Dec. 31 2023 | -0.08 | -0.09 | -0.39 | Missed | -317.9 |
Sep. 30 2023 | -0.14 | -0.15 | -0.41 | Missed | -179.6 |
This summary was machine generated November 1 at 00:26 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)